FDA approves a new pill for hard-to-treat herpes sores
Published
Hovilpri is for adults with weak immune systems whose sores didn't heal on standard antivirals. In a trial, 63% healed fully by day 28 versus 34% on other drugs.
Source: FDA
This is a plain-language summary. Read the original source for full details.